BiomX Inc. Files 8-K on Financials

Ticker: PHGE · Form: 8-K · Filed: Apr 3, 2024 · CIK: 1739174

Biomx Inc. 8-K Filing Summary
FieldDetail
CompanyBiomx Inc. (PHGE)
Form Type8-K
Filed DateApr 3, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, results-of-operations, filing

TL;DR

BiomX filed an 8-K on April 3rd detailing financial condition and results. Check it for the latest on their operations.

AI Summary

BiomX Inc. filed an 8-K on April 3, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The company, formerly known as Chardan Healthcare Acquisition Corp., is incorporated in Delaware and operates in the biological products sector.

Why It Matters

This filing provides crucial updates on BiomX Inc.'s financial health and operational status, which are important for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: medium — BiomX Inc. operates in the biotechnology sector, which is inherently volatile and subject to significant regulatory and scientific risks.

Key Players & Entities

  • BiomX Inc. (company) — Registrant
  • Chardan Healthcare Acquisition Corp. (company) — Former Company Name
  • April 3, 2024 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation

FAQ

What specific financial information is being reported in this 8-K filing?

This 8-K filing reports on BiomX Inc.'s results of operations and financial condition, and includes financial statements and exhibits.

When was this 8-K report filed with the SEC?

The report was filed on April 3, 2024.

What was BiomX Inc.'s former company name?

BiomX Inc.'s former company name was Chardan Healthcare Acquisition Corp.

In which state is BiomX Inc. incorporated?

BiomX Inc. is incorporated in Delaware.

What is the primary business sector of BiomX Inc.?

BiomX Inc. operates in the Biological Products sector, specifically SIC code 2836.

Filing Stats: 459 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-04-03 07:40:57

Key Financial Figures

  • $0.0001 — onsisting of one share of Common Stock, $0.0001 par value, and one Warrant entitling th

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On April 3, 2024, BiomX Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter ended December 31, 2023. A copy of the press release issued in connection with the announcement is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release dated April 3, 2024 (furnished herewith) 104 Cover Page Interactive Data File (embedded within the Inline XBRL documents) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOMX INC. April 3, 2024 By: /s/ Jonathan Solomon Name: Jonathan Solomon Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.